Samuel George A. III has filed 15 insider transactions across 1 company since February 2024.
Most recent transaction: a grant/award of 900000 shares of Lineage Cell Therapeutics, Inc. ($LCTX) on March 05, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | A | Employee Stock Option (Right to Buy) | 900000 | $0.00 | 900,000.0000 | 230,328,000 | 9999.99% | 0.39% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | M | Restricted Stock Units | 6075 | $0.00 | 0.0000 | 230,328,000 | 100.00% | 0.00% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | F | Common Shares | 2502 | $1.80 | 31,063.0000 | 230,328,000 | 7.45% | 0.00% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | M | Common Shares | 6075 | $0.00 | 33,565.0000 | 230,328,000 | 22.10% | 0.00% |
| Dec. 19, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | A | Common Shares | 1735 | $0.00 | 27,555.0000 | 230,328,000 | 6.72% | 0.00% |
| Dec. 19, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | F | Common Shares | 65 | $1.68 | 27,490.0000 | 230,328,000 | 0.24% | 0.00% |
| March 10, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel and Secretary | A | Employee Stock Option (Right to Buy) | 750000 | $0.00 | 750,000.0000 | 220,416,326 | 9999.99% | 0.34% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel | M | Restricted Stock Units | 6076 | $0.00 | 6,075.0000 | 220,416,326 | 50.00% | 0.00% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel | M | Common Shares | 6076 | $0.00 | 28,260.0000 | 220,416,326 | 27.39% | 0.00% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel | F | Common Shares | 2440 | $0.65 | 25,820.0000 | 220,416,326 | 8.63% | 0.00% |
| Nov. 26, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel | P | Common Shares | 15000 | $0.60 | 22,184.0000 | 174,987,000 | 208.80% | 0.01% |
| March 7, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel/Secretary | A | Employee Stock Option (Right to Buy) | 650000 | $0.00 | 650,000.0000 | 174,987,000 | 9999.99% | 0.37% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel/Secretary | F | Common Shares, no par value | 2490 | $1.08 | 7,184.0000 | 174,987,000 | 25.74% | 0.00% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel/Secretary | M | Common Shares, no par value | 6076 | $0.00 | 9,674.0000 | 174,987,000 | 168.87% | 0.00% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Samuel George A. III | General Counsel/Secretary | M | Restricted Stock Units | 6076 | $0.00 | 12,151.0000 | 174,987,000 | 33.34% | 0.00% |